Clinical trials · Minnesota
Metastatic Prostate Cancer clinical trials in Minnesota
We’re tracking 58 recruiting metastatic prostate cancer studies with a site in Minnesota — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Minnesota
- NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
Duluth, MinnesotaAges 18 years+ - NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Rochester, MinnesotaAges 18 years+ - NCT06200103RecruitingPhase 2
Can we pause 177Lu-PSMA-617 therapy after a good response?
This trial tests whether it's safe to pause 177Lu-PSMA-617 therapy in men whose prostate cancer has responded very well to it. Doctors want to see if taking a break from treatment can reduce side effects without letting the cancer come back.
Rochester, MinnesotaAges 18 years+ - NCT06205316RecruitingPhase 3
Radiation therapy for returning or limited-spread prostate cancer
This trial compares two types of radiation therapy for prostate cancer that has come back or spread to a few places after surgery. The goal is to see which radiation schedule works better with fewer side effects.
Albert Lea, MinnesotaAges 18 years+ - NCT06325046Recruiting
Adaptive radiation therapy for localized prostate cancer
This trial tests a type of radiation that adapts to your body's changes during treatment. It is for men with low- to intermediate-risk prostate cancer that hasn't spread.
Albert Lea, MinnesotaAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Rochester, MinnesotaAges 18 years+ - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Rochester, MinnesotaAges 18 years+ - NCT05413421RecruitingPhase 1
ORIC-944 for metastatic prostate cancer after hormone therapy
This early-phase trial tests ORIC-944 to see how well it works and what dose is safest for metastatic prostate cancer that has progressed after hormone-targeted pills. It may help people whose cancer has stopped responding to prior prostate cancer hormone treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT06879041RecruitingPhase 1
Study of a radiation drug for advanced prostate cancer
This trial tests a new drug that delivers radiation directly to cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Rochester, MinnesotaAges 18 years+ - NCT07103018RecruitingPhase 1
Study of KTX-2001 for men with advanced prostate cancer
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
Rochester, MinnesotaAges 18 years+ - NCT07140900RecruitingPhase 1
Study of xaluritamig combined with hormone therapy for advanced prostate cancer
This trial tests a new drug, xaluritamig, given with standard hormone therapy for men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. It aims to see if the combination is safe and works better than hormone therapy alone.
Minneapolis, MinnesotaAges 18 years+ - NCT07285694RecruitingPhase 1/Phase 2
Study of AB-3028 for advanced prostate cancer
This trial tests a new type of immune cell therapy (called AB-3028) designed to recognize and attack prostate cancer cells that have the PSMA protein on their surface. It's for people whose prostate cancer has spread and is no longer controlled by hormone therapy.
Minneapolis, MinnesotaAges 18 years+ - NCT07590934RecruitingPhase 1/Phase 2
Testing new cancer drugs for advanced prostate cancer
This study tests new anti-cancer drugs for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to find treatments that work when standard drugs no longer help.
Minneapolis, MinnesotaAges 18–99 - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Rochester, MinnesotaAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Saint Louis Park, MinnesotaAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Saint Louis Park, MinnesotaAges 18 years+ - NCT07354919RecruitingPhase 2
Testing axelopran for advanced cancer patients on opioids
This trial tests if axelopran can help people with advanced prostate, breast, pancreatic, or lung cancer who are taking opioid pain medicines. It aims to see if the drug is safe and helps with bowel function.
Saint Paul, MinnesotaAges 18 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Minneapolis, MinnesotaAges 18 years+ - NCT04363164RecruitingPhase 2
Testosterone then enzalutamide to stop prostate cancer spread
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
Minneapolis, MinnesotaAges 18–90 - NCT06470243RecruitingPhase 3
Adding carboplatin to cabazitaxel for advanced prostate cancer
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
Cambridge, MinnesotaAges 18 years+ - NCT06136624RecruitingPhase 3
Comparing a new drug to standard hormone therapy for advanced prostate cancer
This trial tests a new pill, opevesostat, against other hormone treatments for men with metastatic castration-resistant prostate cancer that has progressed after previous therapies. It aims to see which approach works better.
Marshall, MinnesotaAges 18 years+ - NCT06952803RecruitingPhase 3
Testing a new drug for men with BRCA-related prostate cancer
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Rochester, MinnesotaAges 18 years+ - NCT06990880RecruitingPhase 1/Phase 2
Study of GSK5458514 alone or with other drugs for prostate cancer
This trial tests a new drug, GSK5458514, either alone or with other cancer treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if the drug can slow down the cancer.
Rochester, MinnesotaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Rochester, MinnesotaAges 18 years+
Metastatic Prostate Cancer trials by city in Minnesota
Where these studies are running in Minnesota
Institutions with a site for the recruiting metastatic prostate cancer studies listed above.
- Mayo Clinic · 8 studies
- Regions Hospital · 6 studies
- University of Minnesota · 4 studies
- HealthPartners Frauenshuh Cancer Center · 3 studies
- Research Site · 3 studies
- Abbott-Northwestern Hospital · 2 studies
- Fairview Southdale Hospital · 2 studies
- Lakeview Hospital · 2 studies
What taking part in a metastatic prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Prostate Cancer trials in other states
Common questions
- Are there metastatic prostate cancer clinical trials in Minnesota?
- Yes. We're currently tracking 58 recruiting metastatic prostate cancer studies with a site in Minnesota, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic prostate cancer study in Minnesota?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Minnesota to take part?
- Not necessarily. These studies have a site in Minnesota, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic prostate cancer studies open in Minnesota regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.